Antiviral activity of ethanol extract of Lophatherum gracile against respiratory syncytial virus infection

被引:26
|
作者
Chen, Li-Feng [1 ]
Zhong, Yuan-Lin [1 ]
Luo, Ding [1 ]
Liu, Zhong [2 ]
Tang, Wei [1 ]
Cheng, Wen [1 ]
Xiong, Si [1 ]
Li, Yao-Lan [1 ]
Li, Man-Mei [1 ]
机构
[1] Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China
[2] Jinan Univ, Coll Life Sci & Technol, Guangzhou Jinan Biomed Res & Dev Ctr, Guangdong Prov Key Lab Bioengn Med, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Lophatherum gracile; Respiratory syncytial virus; Inflammation; Antiviral; Traditional Chinese medicine; IN-VITRO; T-CELLS; PATHOGENESIS; ISOORIENTIN; FLAVONOIDS; PREVENTION; RECEPTORS; LEAVES; HELPER;
D O I
10.1016/j.jep.2018.10.036
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharinacological relevance: Lophatherum gracile, an important medicinal plant, is used traditionally in the treatment of cough associated with lung heat and inflammation. In this study, an ethanol extract of L. gracile (DZY) was shown to inhibit respiratory syncytial virus (RSV) infection and RSV-induced inflammation in vitro and in vivo. These findings provide a strong and powerful support for the traditional use of L. gracile in the treatment of RSV-related diseases. Aim of the study: To determine the anti-RSV activities of DZY and its ingredients, and explore the relationship between RSV infection and inflammation. Materials and methods: DZY was extracted from L. gracile and its major ingredients were determined by high-performance liquid chromatography (HPLC). RSV-infected HEp-2 and RAW264.7 cell models were established to assess the inhibitory effect of DZY on RSV replication and nitric oxide (NO) production in vitro. Three-week-old BALB/c mice challenged intranasally with RSV were used to establish RSV-infected animal mode. The mice were respectively administered DZY at high-, middle-, and low-dose in different groups. The anti-RSV activity of DZY was evaluated by detecting viral load, lung lesion, CD4(+) and CD8(+) T cell population, and interleukin (IL)-1 beta, tumor necrosis factor (TNF)-alpha, and interferon (IFN)-gamma expression in the lung tissue. Results: In HEp-2 cell line, DZY effectively inhibited RSV infection in a dose-dependent manner with IC50 values of 20 mu g/mL against RSV (Long strain) and IC50 values of 25 mu g/mL against RSV (A2 strain). The anti-RSV activity of DZY was mainly determined by isoorientin, swertiajaponin, 3, 5-di-caffeoylquinic acid, and 3, 4-di-caffeoylquinic acid. Moreover, DZY suppressed NO production induced by RSV in vitro. In vivo, oral administration of DZY significantly reduced the viral load and ameliorated lesions in the lung tissue. A probable antiviral mechanism was mediated by slightly improving the ratio of CD4(+)/CD8(+) T cells and inhibiting the mRNA and protein expression of IL-1 beta, TNF-alpha, and IFN-gamma. Conclusions: (1) DZY exhibits anti-RSV activities both in vitro and in vivo. (2) RSV infection can trigger a series of inflammatory reactions; thus, ameliorating inflammation is helpful to control the course of disease caused by RSV. These findings provide the rationale and scientific evidence behind the extensive use of L. gracile in traditional medicine for the treatment of diseases potentially caused by RSV.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Respiratory syncytial virus infection
    Simoes, EAF
    LANCET, 1999, 354 (9181): : 847 - 852
  • [42] RESPIRATORY SYNCYTIAL VIRUS INFECTION
    ROSS, CAC
    STOTT, EJ
    CROWTHER, I
    BMJ-BRITISH MEDICAL JOURNAL, 1964, 1 (5374): : 56 - +
  • [43] IMPACT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION ON HOST FUNCTIONS: IMPLICATIONS FOR ANTIVIRAL STRATEGIES
    Hu, MengJie
    Bogoyevitch, Marie A.
    Jans, David A.
    PHYSIOLOGICAL REVIEWS, 2020, 100 (04) : 1527 - 1594
  • [44] Antiviral activity of a hot water extract of black soybean against a human respiratory illness virus
    Yamai, M
    Tsumura, K
    Kimura, M
    Fukuda, S
    Murakami, T
    Kimura, Y
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2003, 67 (05) : 1071 - 1079
  • [45] An update on respiratory syncytial virus antiviral agents
    Prince, GA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (02) : 297 - 308
  • [46] Treatment of respiratory syncytial virus: antiviral therapies
    Jafri, HS
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (02) : S89 - S93
  • [47] Respiratory Syncytial Virus Provides Protection against a Subsequent Influenza A Virus Infection
    Hartwig, Stacey M.
    Miller, Ann M.
    Varga, Steven M.
    JOURNAL OF IMMUNOLOGY, 2022, 208 (03): : 720 - 731
  • [48] Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers
    Budge, PJ
    Lebowitz, J
    Graham, BS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) : 3470 - 3477
  • [49] Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication
    Luganini, Anna
    Sibille, Giulia
    Pavan, Marta
    Grand, Maurizia Mello
    Sainas, Stefano
    Boschi, Donatella
    Lolli, Marco L.
    Chiorino, Giovanna
    Gribaudo, Giorgio
    ANTIVIRAL RESEARCH, 2023, 219
  • [50] Bivalirudin exerts antiviral activity against respiratory syncytial virus-induced lung infections in neonatal mice
    Zhuang, Shihao
    Tang, Qiuyu
    Chen, Ping
    Wang, Chengyi
    Liu, Guanghua
    ACTA PHARMACEUTICA, 2022, 72 (03) : 415 - 425